Correction: Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells

Wu, Peng; Chen, G.; Wang, B.; Gui, Liming; Liu, Xi; Ma, Xiaoli; Fang, Yong; Zhu, Tao; Wang, D.; Li, Meng; Xu, Gang; Wang, S.; Ma, Ding; Zhou, Jianfeng

doi:10.1038/s41418-021-00829-5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDACis might also affect several biological processes in cancer cells such as apoptotic activity by balancing gene expression via histone methylation or/and acetylation as well as by acetylation of diverse non-histone proteins such as STAT-3, p53 and tubulin. Additionally, HDACis can regulate apoptosis by inducing ubiquitin (UBB) gene expression or Mcl-1 and Bcl-2 [ 138 ], modulate caspase proteins by inducing TRAIL expression, downregulate c-FLIP factors and regulate cell-cycle arrest at active or pathologically proliferative malignant cells [ 139 , 140 , 141 ].…”

Section: Targeting Options Of Hdacis In Sgtsmentioning

confidence: 99%

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options

Manou

Kanakoglou

Loupis

et al. 2023

IJMS

View full text Add to dashboard Cite

Salivary gland tumors (SGTs) comprise a rare and heterogenous category of benign/malignant neoplasms with progressively increasing knowledge of the molecular mechanisms underpinning their pathogenesis, poor prognosis, and therapeutic treatment efficacy. Emerging data are pointing toward an interplay of genetic and epigenetic factors contributing to their heterogeneity and diverse clinical phenotypes. Post-translational histone modifications such as histone acetylation/deacetylation have been shown to actively participate in the pathobiology of SGTs, further suggesting that histone deacetylating factors (HDACs), selective or pan-HDAC inhibitors (HDACis), might present effective treatment options for these neoplasms. Herein, we describe the molecular and epigenetic mechanisms underlying the pathology of the different types of SGTs, focusing on histone acetylation/deacetylation effects on gene expression as well as the progress of HDACis in SGT therapy and the current status of relevant clinical trials.

show abstract